Drug intelligence / Profile preview

dexamethasone + methylprednisolone

Development stage: Unknown
Lead developer: Merck
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral, Injectable, Ophthalmic

Overview

A combination of two potent corticosteroids, dexamethasone and methylprednisolone, used for their enhanced anti-inflammatory, immunosuppressive, and anti-allergic effects. Dexamethasone is a long-acting corticosteroid while methylprednisolone has a shorter duration of action. This combination has been used in treating severe paraquat poisoning, inflammatory conditions, and as part of COVID-19 treatment protocols.

Other names: perioperative glucocorticoidsSAFE Trial intervention

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on dexamethasone + methylprednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexamethasone + methylprednisolone.

Explore the full profile